Four-year Prostate-specific Antigen Response Rate as a Predictive Measure in Intermediate-risk Prostate Cancer Treated With Ablative Therapies: The SPRAT Analysis. - Glicksman, R.M.; Kishan, A.U.; Katz, A.J.; Mantz, C.A.; Collins, S.P.; Fuller, D.B.; Steinberg, M.L.; Shabsovich, D.; Zhang, L.; Loblaw, A. (Clinical Oncology, 2022)